F. Gieseler et al., Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage, LEUKEMIA, 13(11), 1999, pp. 1859-1863
We examined the cellular effects of topo II inhibitors in two human myeloid
cell lines, HL-60 and KG-1 cells, with the purpose of finding molecular ma
rkers for the sensitivity of leukemia cells to topo II inhibitors, These ce
ll lines are widely used, well characterized and they differ in their sensi
tivities to topo II inhibitors. Despite the fact that HL-60 cells are p53-n
egative, they are much more sensitive than KG-1 cells. Three different topo
II inhibitors with distinct molecular ways of action have been used. Dauno
rubicin acid aclarubicin are DNA intercalators that secondarily interact wi
th topo II; etoposide, on the other hand, directly binds to the enzyme. In
contrast to daunorubicin, which induces protein-associated DNA double-stran
d breaks due to the blockage of topo II action, aclarubicin inhibits the ac
cess of DNA by topo II. No correlation could be established between the dru
g-induced DNA damage and apoptosis. In fact, the amount and pattern of DNA
damage examined with the 'comet assay' was characteristic for each drug in
both cell lines. The DNA binding of daunorubicin was slightly higher in HL-
60 cells, but there was no notable variance between the cell lines for acla
rubicin. The most striking difference could be found for the nuclear topo I
I activity, which was about half in KG-I cells and, additionally, less than
1% of the nuclear topo II activity was bound to the DNA in KG-I cells when
compared to HL-60 cells. This fraction of topo II interacts with the inhib
itors; subsequently these findings might well explain the variance in the c
ellular sensitivity. Additional factors are alterations of the apoptotic pa
thways, eg loss of p53 in HL-60 cells. Although we found no differences in
the quantity of DNA damage between the cell lines after drug treatment, the
quality of DNA damage appeared to be distinct for each topo II inhibitor.
The morphological appearance of the comet tails after treatment was charact
eristic for each drug. Further studies are necessary to decide whether thes
e in vitro data are compatible with the clinical situation.